Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 19/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140881 | 0.95 | PSMB5 (0.71) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3153448 | 0.95 | PSMB5 (0.71) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL3144638 | 0.91 | PSMB5 (0.62) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3143650 | 0.90 | PSMB5 (0.59) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16478941 | 0.86 | PSMB5 (0.68) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3136345 | 0.85 | PSMB5 (0.64) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL3149041 | 0.84 | PSMB5 (0.63) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14814853 | 0.83 | PSMB5 (0.89) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19381911 | 0.83 | PSEN1 (0.68) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3135741 | 0.83 | PSEN1 (0.68) | PSMB5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035811-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170349611-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9771381-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2346882-B1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARM INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20140194387-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8664200-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSEN1 150/4885PSEN2 309/4885 |
| US-20140194387-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSEN1 150/4885PSEN2 309/4885 |
| US-10035811-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSEN1 150/4885PSEN2 309/4885 |
| US-20170349611-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSEN1 150/4885PSEN2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.